EnsiliTech
Bristol
About EnsiliTech
Ensilication® is a patent protected, novel method for encasing thermally unstable biomolecules within a silica network to prevent degradation at temperatures from –80 to +50 °C, and improved shelf-life. The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics, preventing wastage, improving shelf-life and increasing the accessibility of biological therapeutics and diagnostics globally. Unlike other stabilisation technologies, ensilication does not rely on lyophilisation or any harsh conditions. The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $11.5M
- Funding stage: Seed
- Last round: Seed (Aug 2025)
- Website: ensilitech.com
- Phone: [email protected]
Industries & Categories
Biopharma, Medical, Pharmaceutical, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/ensilitech-38477 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.